What began with a visit to a retina specialist as a young patient with myopia has evolved into a lifelong interest and career path in the retina field for Katherine Talcott, M.D. In this month’s #EyesOnTheRise, Dr. Talcott reflects on how therapeutic advances, a close-knit retina community, and strong mentors have shaped both her journey and perspective on the specialty. EyePoint has partnered with Dr. Talcott to share her own views for educational purposes only. Her statements are not intended as medical advice.
EyePoint
Biotechnology Research
Watertown, MA 18,980 followers
Committed to developing innovative therapeutics to improve the lives of people with serious retinal diseases.
About us
EyePoint (Nasdaq: EYPT) is a clinical-stage biopharmaceutical company committed to developing and commercializing innovative therapeutics to improve the lives of people with serious retinal diseases. Our lead product candidate is an innovative investigational sustained delivery treatment for VEGF-mediated retinal diseases combining a selective and patent-protected tyrosine kinase inhibitor in next-generation bioerodible technology. Supported by robust safety and efficacy data to date, we are presently in Phase 3 global, pivotal clinical trials for wet age-related macular degeneration, with topline data anticipated in 2026. We have also completed a positive Phase 2 clinical trial in diabetic macular edema (DME) with Phase 3 pivotal planning underway. Despite current therapies, patients with wet AMD and DME still tend to lose vision in the long term and wet AMD the leading cause of vision loss among people 50 years of age and older in the United States. We are committed to partnering with the retina community to improve patient lives while creating long-term value, with four approved drugs over three decades and tens of thousands of eyes treated with EyePoint innovation. Driven by our core values – Transformational Innovation, Unwavering Integrity, Compassionate Excellence, and Inclusive Collaboration, our team is dedicated to achieving our shared vision for the future and bettering the lives of patients, caregivers and healthcare professionals. EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
- Website
-
https://eyepoint.bio/
External link for EyePoint
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- Watertown, MA
- Type
- Public Company
- Specialties
- Ophthalmology, Optometry, Eye Disease, Retinal Disease, Diabetic Macular Edema (DME), and Wet Age-Related Macular Degeneration (AMD)
Locations
-
Get directions
480 Pleasant St., Suite B300
Watertown, MA 02472, US
Employees at EyePoint
Updates
-
Hear from Chief People Officer Jennifer Leonard, who shares how we are taking a holistic approach to employee well-being this Mental Health Awareness Month.
Mental health doesn’t exist in a vacuum. It’s shaped by how supported we feel, how secure our lives are, how often we move our bodies, and whether the work we do feels meaningful. Over time, I have come to see well‑being as something sustained through a combination of habits, resources, and culture. When those elements come together, people are better able to show up with focus and a sense of purpose. At EyePoint, we take a holistic view of employee well‑being. This Mental Health Awareness Month, we’ve focused on supporting the whole person through practical efforts, like: • A Mind Body Challenge that blends movement and guided meditation, helping employees build habits they can sustain well beyond May. • Chair massages to encourage rest and recovery during the workday. • Financial wellness sessions with Fidelity Investments and Creative Planning. • Employee and manager sessions with our Employee Assistance Program partner to make support easier to understand and access. • A Mental Health Toolkit with resources our team can use year‑round. Mental health is also shaped by how connected and fulfilled people feel in their roles. When individuals understand the purpose behind their work and feel supported, it strengthens both well‑being and performance. Taking a holistic approach means looking beyond individual programs to the environment people experience every day. We strive to create a workplace where people can thrive and grow. That includes business accomplishments, like fully enrolling a Phase 3 clinical program, scaling manufacturing for a globally commercialized therapy, or advancing new discoveries in the lab, alongside moments of connection and fun, such as Third Thursday happy hours or our Annual Summer Outing. We also come together to support communities in meaningful ways like participating in The Carroll Center for the Blind’s Walk for Independence. Mental health support looks different to everyone, and I’d love to hear from you. What are some ways you support your mental health, at work or personally? #LifeAtEyePoint
-
-
For people living with wet AMD, missed appointments remain a persistent challenge, particularly among patients managing frequent treatment schedules. While current therapies have advanced care, treatment burden remains an important, and often under-discussed, challenge. At EyePoint, our mission is to help address these challenges by advancing approaches that aim to improve outcomes while reducing frequency of follow up treatments. Learn more: https://lnkd.in/gQ7HW5mv
-
-
UPDATE! The Independent Data Safety Monitoring Committee (DSMC) has issued a third positive recommendation for our pivotal Phase 3 wet AMD program. 📈 We continue to advance the LUGANO and LUCIA trials with no protocol modifications, and topline data are expected beginning mid‑2026. This latest DSMC review reinforces consistency of the safety profile observed across our wet AMD program and strengthens our confidence in bringing a new treatment option to patients. 👉 Learn more here: https://lnkd.in/gChUWjvt
-
Despite advances in treatment, many patients living with wet AMD and DME still face challenges. At EyePoint, we're aiming to update the treatment paradigm for serious retinal diseases by creating best-in-class, durable therapies, working to improve patient outcomes while reducing the need for frequent follow-up visits. See more on our programs: https://lnkd.in/g9EcudGQ
-
Team EyePoint is attending the Retina World Congress to discuss the latest research in retinal diseases. A presentation of results from the Phase 2 DAVIO 2 clinical trial will be delivered by Priya Vakharia, M.D. We look forward to the scientific discussion at the meeting!
-
-
In a recent interview with Ophthalmology 360®, Deepak Sambhara MD, FASRS, discussed current unmet needs and emerging treatment approaches for patients with AMD and DME. Read the full Q&A: https://lnkd.in/dXmtFQYd Disclaimer: EyePoint has partnered with Dr. Sambhara to share his own views for educational purposes only. The investigational therapy discussed has not been approved by the FDA. FDA approval and the timeline for potential approval is uncertain.
-
-
Wet AMD and DME are complex, multifactorial diseases that require more than VEGF suppression. Learn about a multi-MOA TKI designed to block VEGF and PDGF at the receptor level, while also inhibiting IL-6 pro-inflammatory signaling. Explore EYP-1901 at: https://uniqode.io/zhp2P8
-
#InvestorNews: #EYPT reports Q1 2026 financial results and highlights recent corporate developments. See more on our latest pivotal Phase 3 trial progress and recent corporate updates here: https://lnkd.in/g5aqkkEC
-
-
Team EyePoint is in Denver, CO, for Association for Research in Vision and Ophthalmology (ARVO)’s 2026 Annual Meeting! We’ll be connecting, learning, and engaging with leading experts on the latest advancements in retina. See you there! #ARVO2026
-